AstraZeneca has put a lot of resources behind its aging blood thinner Brilinta, hoping to keep the anticoagulant's place in doctors' minds fresh for years to come. With a suite of new data and ...
The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca's struggling oral antiplatelet drug. The collaboration is the first stage of "a global ...
Guidelines based on study showing BRILINTA reduces risk of cardiovascular events over clopidogrel in patients with Acute Coronary Syndrome WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) ...
(CBS/AP) The FDA has approved the blood thinner Brilinta, and that means there's an alternative to the blockbuster pill Plavix for patients who have clogged arteries associated with a condition known ...
The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events. The Food and Drug ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for ...
Almost four years after failing to outperform aspirin in preventing stroke in high-risk patients, AstraZeneca’s Brilinta has hit the mark in a new phase 3 trial. This time round, AZ evaluated Brilinta ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with ...
AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD). The ...
LONDON, Oct 4 (Reuters) - AstraZeneca's heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a ...
BRILINTA indicated to reduce heart attacks and cardiovascular death in patients with Acute Coronary Syndrome WILMINGTON, Del. - AstraZeneca announced today that the US Food and Drug Administration ...
The parade of investigations launched by government agencies into a big drugmaker is often shrugged off, at least by investors, who play wait-and-see since the outcome of such probes can, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback